Table 2.

Univariate and multivariate analyses of factors associated with time to HIV-1 RNA < 500 copies/mL among individuals beginning antiretroviral therapy

Characteristic	Hazard Ratio	95% CI3	p-value	Adjusted Hazard Ratio	95% CI3	p-value
Physician experience1
Per 100 patients	1.25	1.10-1.42	< 0.001	1.17	1.04-1.34	0.031
Age1
Per 10 years	1.26	1.08-1.47	0.004
Gender1
Female vs. male	0.95	0.73-1.24	0.711
Aboriginal ancestry1
Yes vs. no	1.05	0.80-1.36	0.103
DTES residence2
Yes vs. no	1.13	0.86-1.49	0.788
Methadone maintenance2
Yes vs. no	1.54	1.18-2.00	0.001	1.61	1.23-2.09	< 0.001
Daily cocaine use2
Yes vs. no	0.92	0.68-1.24	0.578
Daily heroin use2
Yes vs. no	0.78	0.57-1.08	0.137
ART adherence2
> 95% vs. ≤ 95%	4.12	3.10-5.54	< 0.001	2.42	1.80-3.26	< 0.001
PI in first regimen1
Yes vs. no	1.23	0.95-1.61	0.117
CD4 cell count1
Per 100 cells	0.90	0.84-0.96	0.003	0.89	0.83-0.96	0.001
Plasma viral load1
Per log10 increase	0.71	0.58-0.87	0.001	0.65	0.53-0.81	< 0.001
Year of ART initiation1
Per more recent year	1.17	1.12-1.21	< 0.001

1. Time invariant, observed at baseline

2. Time varying, observed every 6 months

3. 95% Confidence Interval